Patents by Inventor Young-Ah Moon

Young-Ah Moon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Apparatus and method of analyzing developed impact marks, and computer program for executing the method
    Patent number: 11995887
    Abstract: A developed impact mark analysis apparatus includes: an image acquisition unit configured to obtain at least one first image by photographing impact marks that are developed, and to obtain a second image of impact marks at a crime scene that are developed from evidence at the crime scene; an outliner configured to outline the at least one first image to obtain at least one first outline image, and to outline the second image to obtain a second outline image; a database configured to store the first outline image corresponding to related tool characteristic information; a matching unit configured to search the database for the first outline image determined to be similar to the second outline image and match them with each other; a display unit; and a user input unit.
    Type: Grant
    Filed: November 3, 2021
    Date of Patent: May 28, 2024
    Assignee: REPUBLIC OF KOREA (NATIONAL FORENSIC SERVICE DIRECTOR MINISTRY OF THE INTERIOR AND SAFETY)
    Inventors: Nam Kyu Park, Byung Seon Moon, Jae Mo Goh, Jin Pyo Kim, Young Il Seo, Eun Ah Joo, Je Hyun Lee, Sang Yoon Lee
  • RNAI MODULATION OF SCAP AND THERAPEUTIC USES THEREOF
    Publication number: 20160068840
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a SCAP gene (Human SCAP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a SCAP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Human SCAP expression and the expression of a SCAP gene using the pharmaceutical composition; and methods for inhibiting the expression of a SCAP gene in a cell.
    Type: Application
    Filed: July 8, 2015
    Publication date: March 10, 2016
    Inventors: Juergen SOUTSCHEK, Pamela TAN, Jay D. HORTON, Michael S. BROWN, Joseph L. GOLDSTEIN, Young-Ah MOON
  • RNAi modulation of SCAP and therapeutic uses thereof
    Patent number: 9102940
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a SCAP gene (Human SCAP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a SCAP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Human SCAP expression and the expression of a SCAP gene using the pharmaceutical composition; and methods for inhibiting the expression of a SCAP gene in a cell.
    Type: Grant
    Filed: January 17, 2013
    Date of Patent: August 11, 2015
    Assignees: Alnylam Pharmaceuticals, Inc., Board of Regents, The University of Texas System
    Inventors: Juergen Soutschek, Pamela Tan, Jay D. Horton, Michael S. Brown, Joseph L. Goldstein, Young-Ah Moon
  • RNAi modulation of SCAP and therapeutic uses thereof
    Patent number: 8383805
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a SCAP gene (Human SCAP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a SCAP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Human SCAP expression and the expression of a SCAP gene using the pharmaceutical composition; and methods for inhibiting the expression of a SCAP gene in a cell.
    Type: Grant
    Filed: April 5, 2011
    Date of Patent: February 26, 2013
    Assignees: Alnylam Pharmaceuticals, Inc., Board of Regents, The University of Texas System
    Inventors: Juergen Soutschek, Pamela Tan, Jay D. Horton, Michael S. Brown, Joseph L. Goldstein, Young-Ah Moon
  • RNAI MODULATION OF SCAP AND THERAPEUTIC USES THEREOF
    Publication number: 20110184047
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a SCAP gene (Human SCAP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a SCAP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Human SCAP expression and the expression of a SCAP gene using the pharmaceutical composition; and methods for inhibiting the expression of a SCAP gene in a cell.
    Type: Application
    Filed: April 5, 2011
    Publication date: July 28, 2011
    Inventors: Juergen Soutschek, Pamela Tan, Jay D. Horton, Michael S. Brown, Joseph L. Goldstein, Young-Ah Moon
  • RNAi modulation of SCAP and therapeutic uses thereof
    Patent number: 7919613
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a SCAP gene (Human SCAP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a SCAP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Human SCAP expression and the expression of a SCAP gene using the pharmaceutical composition; and methods for inhibiting the expression of a SCAP gene in a cell.
    Type: Grant
    Filed: March 29, 2010
    Date of Patent: April 5, 2011
    Assignees: Alnylam Pharmaceuticals, Inc., Board of Regents, the Unversity of Texas System
    Inventors: Juergen Soutschek, Pamela Tan, Jay D. Horton, Michael S. Brown, Joseph L. Goldstein, Young-Ah Moon
  • RNAI MODULATION OF SCAP AND THERAPEUTIC USES THEREOF
    Publication number: 20100184829
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a SCAP gene (Human SCAP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a SCAP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Human SCAP expression and the expression of a SCAP gene using the pharmaceutical composition; and methods for inhibiting the expression of a SCAP gene in a cell.
    Type: Application
    Filed: March 29, 2010
    Publication date: July 22, 2010
    Inventors: Juergen Soutschek, Pamela Tan, Jay D. Horton, Michael S. Brown, Joseph L. Goldstein, Young-Ah Moon
  • RNAi modulation of SCAP and therapeutics uses thereof
    Patent number: 7737266
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a SCAP gene (Human SCAP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a SCAP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Human SCAP expression and the expression of a SCAP gene using the pharmaceutical composition; and methods for inhibiting the expression of a SCAP gene in a cell.
    Type: Grant
    Filed: September 18, 2007
    Date of Patent: June 15, 2010
    Assignees: Board of Regents, The University of Texas System, Alnylam Pharmaceuticals, Inc.
    Inventors: Juergen Soutschek, Pamela Tan, Jay D. Horton, Michael S. Brown, Joseph L. Goldstein, Young-Ah Moon
  • RNAI MODULATION OF SCAP AND THERAPEUTIC USES THEREOF
    Publication number: 20090093426
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a SCAP gene (Human SCAP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a SCAP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Human SCAP expression and the expression of a SCAP gene using the pharmaceutical composition; and methods for inhibiting the expression of a SCAP gene in a cell.
    Type: Application
    Filed: September 18, 2007
    Publication date: April 9, 2009
    Inventors: Juergen Soutschek, Pamela Tan, Jay D. Horton, Michael S. Brown, Joseph L. Goldstein, Young-Ah Moon